A different study identified PD-L2 expression in 63.2% (31/49) of ENKTL cases with a cutoff value of ≥10%, while a subgroup analysis based on PD-L1/2 expression status showed superior EFS and OS in patients lacking PD-L expression on tumor cells. The gene discussed is CD274; the disease is neoplasm.